Wang Guomin, Zhou Bo, Zheng Lifeng, Ni Yanfei, Pan Anle
Psychiatric Department, the Third Hospital of Quzhou, Quzhou, China.
Psychiatric Department, the Affiliated Kangning Hospital of Wenzhou Medical University, Wenzhou, China.
Ann Palliat Med. 2020 Sep;9(5):3481-3487. doi: 10.21037/apm-20-1702.
Aminosulpiride is a benzamide used to treat acute or chronic schizophrenia Some researchers believe that early improvement of depression symptoms in patients has a certain predictive effect on the recovery of symptoms after drug treatment for schizophrenia. This study is aimed to explore whether the improvement of depression symptoms is a predictive factor for the amelioration of the schizophrenia symptoms by amisulpride treatment.
A total of 383 patients with schizophrenia admitted to 15 hospitals in Fujian and Zhejiang from July 1, 2018 to March 31, 2019 were included in the study. The patients were treated with amisulpride tablets with a dose strategy of 200-1,200 mg/d for 8 weeks. The Positive and Negative Affect Scale (PANAS) was used as the criteria to evaluate the treatment effect, including criterion A and criterion B. After the course of treatment, the improvement of depression symptoms was compared between the remission group and the non-remission group. Logistic regression analysis was used to investigate predictors of symptom relief in schizophrenia patients treated with amisulpride.
Of the 383 subjects with schizophrenia, 303 completed the 8-week treatment with amisulpride, and 244 (80.53%) achieved remission of symptoms after the treatment, satisfying criterion A. In 258 patients (85.15%), the symptoms were relieved and satisfied criterion B, while there was no significant difference between the number of patients who met criterion A and those who met criterion B (P>0.05). Both the remission group and the non-remission group had obvious improvement in depression symptoms. Furthermore, the remission group showed a more significant improvement in depression symptoms after the treatment. Logistic regression analysis revealed that the improvement of depression symptoms cannot be used as a predictor of symptomatic relief with amisulpride in the treatment of schizophrenia according to criterion A (B=-0.01, P=0.07). While under the criterion B, the patient's age could be used as a predictive factor of symptom remission from amisulpride in the treatment of schizophrenia (B=-0.08, P=0.03).
Amisulpride is effective in the treatment of schizophrenia and improving depression symptoms. The improvement of depression symptoms has no significant predictive effect on the remission of schizophrenia symptoms.
氨磺必利是一种用于治疗急性或慢性精神分裂症的苯甲酰胺类药物。一些研究者认为，患者抑郁症状的早期改善对精神分裂症药物治疗后症状的恢复有一定的预测作用。本研究旨在探讨抑郁症状的改善是否是氨磺必利治疗精神分裂症症状改善的预测因素。
纳入2018年7月1日至2019年3月31日在福建和浙江15家医院收治的383例精神分裂症患者。患者接受氨磺必利片治疗，剂量策略为200 - 1200mg/d，疗程8周。采用正负性情绪量表（PANAS）作为评估治疗效果的标准，包括标准A和标准B。治疗疗程结束后，比较缓解组和未缓解组抑郁症状的改善情况。采用Logistic回归分析探讨氨磺必利治疗精神分裂症患者症状缓解的预测因素。
383例精神分裂症患者中，303例完成了8周的氨磺必利治疗，其中244例（80.53%）治疗后症状缓解，达到标准A。258例患者（85.15%）症状减轻，达到标准B，达到标准A和标准B的患者数量无显著差异（P>0.05）。缓解组和未缓解组的抑郁症状均有明显改善。此外，缓解组治疗后抑郁症状改善更显著。Logistic回归分析显示，根据标准A，抑郁症状的改善不能作为氨磺必利治疗精神分裂症症状缓解的预测指标（B=-0.01，P=0.07）。而在标准B下，患者年龄可作为氨磺必利治疗精神分裂症症状缓解的预测因素（B=-0.08，P=0.03）。
氨磺必利治疗精神分裂症及改善抑郁症状有效。抑郁症状的改善对精神分裂症症状的缓解无显著预测作用。
